The Aducanumab Aftermath: The Patient

Desperate to slow her cognitive decline, one patient shares her hopes and concerns about the first new Alzheimer’s drug in nearly 20 years.This episode is part of a special weeklong series examining the potentially sweeping consequences this drug, known as aducanumab, could have on millions of patients’ lives and billions of dollars in health care spending.Guest: Arthena Caston, Alzheimer’s patient and advocateExplore the full series and additional resources: https://tradeoffs.org/aducanumabRead a transcript of this episode: https://tradeoffs.org/2021/06/23/the-aducanumab-aftermath-the-patient/Sign up for our weekly newsletter to see what research health policy experts are reading right now, plus recommendations from our staff: bit.ly/tradeoffsnewsletterSupport this type of journalism today, with a gift: https://tradeoffs.org/donateFollow us on Twitter: https://twitter.com/tradeoffspod Hosted on Acast. See acast.com/privacy for more information.